McMurray, John J.V.

Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021

Malik, M. E., Falkentoft, A. C., Jensen, J., Zahir, D., Parveen, S., Alhakak, A., Andersson, C., Petrie, M. C., Sattar, N., McMurray, J. J. V., et al. (2023) · The Lancet Regional Health - Europe

Diabetes Treatment and ManagementMedication Adherence and Compliance

Cited by 67

Discordant Short- and Long-Term Outcomes Associated With Diabetes in Patients With Heart Failure: Importance of Age and Sex: A Population Study of 5.1 Million People in Scotland

MacDonald, M. R., Jhund, P. S., Petrie, M. C., Lewsey, J. D., Hawkins, N. M., Bhagra, S., Munoz, N., Varyani, F., Redpath, A., Chalmers, J., et al. (2008) · Circulation Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 64

Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials

McMurray, J. J. V., Docherty, K. F., de Boer, R. A., Hammarstedt, A., Kitzman, D. W., Kosiborod, M. N., Maria Langkilde, A., Reicher, B., Senni, M., Shah, S. J., et al. (2024) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 60

Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial

Kraus, W. E., Yates, T., Tuomilehto, J., Sun, J.-L., Thomas, L., McMurray, J. J. V., Bethel, M. A., & Holman, R. R. (2018) · BMJ Open Diabetes Research & Care

Physical Activity and HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 59

Digitalis for treatment of heart failure in patients in sinus rhythm

Hood Jr., W. B., Dans, A. L., Guyatt, G. H., Jaeschke, R., & McMurray, J. J. (2014) · Cochrane Database of Systematic Reviews

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 56

Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF

Feinstein, M. J., Jhund, P., Kang, J., Ning, H., Maggioni, A., Wikstrand, J., Kjekshus, J., Tavazzi, L., McMurray, J., & Lloyd-Jones, D. M. (2015) · European Journal of Heart Failure

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 56

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR

Huffman, K. M., Sun, J.-L., Thomas, L., Bales, C. W., Califf, R. M., Yates, T., Davies, M. J., Holman, R. R., McMurray, J. J. V., Bethel, M. A., et al. (2014) · Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsPhysical Activity and Health

Cited by 45

Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy

Docherty, K. F., Jhund, P. S., Bengtsson, O., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 44

Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction

Docherty, K. F., Shen, L., Castagno, D., Petrie, M. C., Abraham, W. T., Böhm, M., Desai, A. S., Dickstein, K., Køber, L. V., Packer, M., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 42

Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF

Yang, M., Henderson, A. D., Talebi, A., Atherton, J. J., Chiang, C.-E., Chopra, V., Comin-Colet, J., Kosiborod, M. N., Kerr Saraiva, J. F., Claggett, B. L., et al. (2025) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementHormonal Regulation and Hypertension

Cited by 41

Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibition According to Left Ventricular Ejection Fraction in DAPA-HF

Dewan, P., Solomon, S. D., Jhund, P. S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., DeMets, D. L., Sabatine, M. S., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 41

Effect of SGLT2 inhibitors on discontinuation of renin-angiotensin system blockade: a joint analysis of the CREDENCE and DAPA-CKD trials

Fletcher, R. A., Jongs, N., Chertow, G. M., McMurray, J. J. V., Arnott, C., Jardine, M. J., Mahaffey, K. W., Perkovic, V., Rockenschaub, P., Rossing, P., et al. (2023) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 40

Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence

Khunti, K., Aroda, V. R., Bhatt, D. L., Bozkurt, B., Buse, J. B., Heerspink, H. L., Inzucchi, S. E., Lam, C. S. P., Marx, N., McMurray, J. J. V., et al. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 37

Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial

Lee, M. M. Y., Kristensen, S. L., Gerstein, H. C., McMurray, J. J. V., & Sattar, N. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 37

Health‐related quality of life outcomes in PARAGON‐HF

Chandra, A., Polanczyk, C. A., Claggett, B. L., Vaduganathan, M., Packer, M., Lefkowitz, M. P., Rouleau, J. L., Liu, J., Shi, V. C., Schwende, H., et al. (2022) · European Journal of Heart Failure

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 33

Myocardial Infarction in Heart Failure With Preserved Ejection Fraction

Cunningham, J. W., Vaduganathan, M., Claggett, B. L., John, J. E., Desai, A. S., Lewis, E. F., Zile, M. R., Carson, P., Jhund, P. S., Kober, L., et al. (2020) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 33

Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: an analysis of the Digitalis Investigation Group (DIG) trial

Abdul-Rahim, A. H., MacIsaac, R. L., Jhund, P. S., Petrie, M. C., Lees, K. R., & McMurray, J. J. V. (2016) · International Journal of Cardiology

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 29

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Beernink, J. M., Persson, F., Jongs, N., Laverman, G. D., Chertow, G. M., McMurray, J. J. V., Langkilde, A. M., Correa-Rotter, R., Rossing, P., Sjöström, C. D., et al. (2023) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 18

Natural language processing to adjudicate heart failure hospitalizations in global clinical trials

Marti-Castellote, P. M., Reeder, C., Claggett, B., Singh, P., Lau, E. S., Khurshid, S., Batra, P., Lubitz, S. A., Maddah, M., Vardeny, O., et al. (2025) · Circulation: Heart Failure

Artificial Intelligence in HealthcareHeart Failure Treatment and Management

Cited by 14

Updated risk factors should be used to predict development of diabetes

Bethel, M. A., Hyland, K. A., Chacra, A. R., Deedwania, P., Fulcher, G. R., Holman, R. R., Jenssen, T., Levitt, N. S., McMurray, J. J. V., Boutati, E., et al. (2017) · Journal of Diabetes and its Complications

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 12

Chronic obstructive pulmonary disease and cardiovascular risk: Insights from the NAVIGATOR trial

de Barros e Silva, P. G. M., Califf, R. M., Sun, J.-L., McMurray, J. J. V., Holman, R., Haffner, S., Thomas, L., & Lopes, R. D. (2014) · International Journal of Cardiology

Chronic Obstructive Pulmonary Disease (COPD) ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 11

Meta‐analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin

McMurray, J. J. V., Solomon, S. D., Lock, J. P., Massaro, J. M., Zhu, F., Zhou, W., Skali, H., Lewis, E. F., Freeman, M. W., & Halvorsen, Y. C. (2024) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 9